Recombinant Human Polyclonal Antibodies to Treat Disease

Publications
Published on:
April 26, 2021
Written by:
Steven Chamow, Bryan Monroe, Chuck Olson

Congratulations to Alira Health’s Steven Chamow, PhD, Senior Vice President, CMC and founder of Chamow & Associates, and to Bryan Monroe and Chuck Olson, Senior Consultants, on their contributions to “Generation of recombinant hyperimmune globulins from diverse B-cell repertoires” published in the current issue of Nature Biotechnology.

The publication by Sheila Keating, Rena Mizrahi and colleagues is a result of a large collaborative effort organized and coordinated by GigaGen, Inc., a US biotechnology company specializing in the discovery and development of recombinant biotherapeutic medicines. It describes a microfluidics and molecular genomics strategy for capturing diverse mammalian antibody repertoires to create recombinant multivalent antibodies.

This novel method generates mixtures of thousands of recombinant antibodies; mixtures that are enriched for antibodies with specificity and activity against predefined therapeutic targets. The antibodies are derived from convalescent or vaccinated human donors or from immunized mice.

Because the method produces cell lines in which multiple copies of the expression construct are present in the genome, insertion cannot be random. Steve’s team guided the use of CHO cell lines engineered with a Flp recombinase recognition target landing pad to achieve stable expression of recombinant heavy and light chains in polyclonal cell banks.

GigaGen reports that it has generated potent hyperimmune recombinant polyclonal antibody therapies against SARS-CoV-2, Zika virus and human thymocytes, the latter to treat graft-versus-host disease.

Click here to access the full publication.

For more information, contact Steven Chamow.

Related news

News June 17, 2022
Music Beats Cancer Hosts Reception at BIO International Convention in San Diego
Music Beats Cancer hosted a reception fostering a networking community for innovators working on promising solutions for cancer.
Crowdfunding Patient Centricity Research & Development
Events May 9, 2022
7e Journée start-up innovantes du dispositif médical
Clinical Digital Health Market Access MedTech Research & Development
News April 5, 2022
Alira Health Strengthens Clinical Operations with the Acquisition of Sourcia
We acquired a full-service Contract Research Organization (CRO), Sourcia, that provides services for Phase I to Phase IV clinical trials with a focus on biotech, medical devices, and(...)
Clinical MedTech Patient Engagement Pharma Regulatory Research & Development
Publications December 10, 2021
Leveraging Data Intelligence for Effective Opportunity Screening and Prioritization in Drug Discovery
Our biotech client needed an innovative, effective way to identify which binding sites and therapeutic indications they should target for the development of new therapeutic agents for(...)
Advanced Analytics Digital Health Pharma Research & Development
Events November 24, 2021
Event: Innovations In Wound Healing Annual Conference
Join Dr. Mitch Sanders for an exclusive poster session at this event.
Research & Development
Events October 20, 2021
Event: SAWC Fall 2021
Join Dr. Sanders at SAWC Fall in Las Vegas, NV.
Research & Development
Publications August 18, 2021
Infographic: Indication Prioritization and Pre-Commercial Value Assessment
Download our infographic on Indication Prioritization and Pre-Commercial Value Assessment.
Due Diligence Research & Development
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.